Discover and read the best of Twitter Threads about #CTAD
Most recents (2)
My thoughts on the phase 3 results of Alzheimer's drug lecanemab from Biogen and Eisai, presented at #CTAD #CTAD22 and published this evening in the @NEJM. Major takeaway – this is NOT the breakthrough we have been waiting for. Key points: 
1) This trial is much better than the frustrating data associated with Aducanumab. Demographics are well balanced between groups and are (somewhat) more representative, the protocol is coherent and there aren’t major technical problems.
The drug clearly engaged its target, massively lowering β-amyloid levels in the first year of treatment based on amyloid PET scans.
BREAKING NEWS: New #Alzheimer drug #Lecanemab slows cognitive decline (18-month change in CDR-SB) by 27%, drastically lowers brain amyloid load by 59 centiloids to 23 (below PET amyloid positivity)! NEJM paper: nejm.org/doi/full/10.10… prnewswire.com/news-releases/… #CTAD
Randy Bateman notes that lecanemab reverses amyloid levels; 20 centiloid drop in amyloid levels at 3 months and 50 centiloid drop by 1 year on neuroimaging measures #CTAD2022
..also slows decreases in the rate of tau accumulation in the temporal lobes which is important for cognition #CTAD2022
